IN THE NEWS
July 2, 2018:
Fortress Biotech Announces Cyprium Therapeutics' CUTX-101 (Copper Histidinate) Granted FDA Fast Track Designation for Treatment of Classic Menkes Disease
June 25, 2018:
Caelum Biosciences Announces Complete Cardiac Data Analysis from Phase 1b Trial of CAEL-101 in AL Amyloidosis
Mustang Bio Added to Russell 2000®, 3000® and Microcap® Indexes
June 22, 2018:
Mustang Bio Announces Opening of CAR T Cell Therapy Manufacturing Facility in Worcester, Mass.
June 19, 2018:
Fortress Biotech Announces Publication of Phase 1 Data on CNDO-109-Activated Allogeneic Natural Killer Cells in Acute Myeloid Leukemia in Biology of Blood and Marrow Transplantation
Avenue Therapeutics to Participate in JMP Securities Life Sciences Conference
QUICK LINKS
PIPELINE
.gif)
